Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Liquidia Corporation - Common Stock (NQ:LQDA)

24.54 +0.52 (+2.14%)
Streaming Delayed Price Updated: 2:16 PM EDT, Oct 8, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Liquidia Corporation - Common Stock

< Previous 1 2 3 4 5 6 Next >
What 5 Analyst Ratings Have To Say About Liquidia
 
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga
Why United Therapeutics Just Catapulted 35%, Pulling Insmed, Liquidia With It
The company sells Tyvaso, a treatment for lung diseases. On Tuesday, Tyvaso showed promise, again, in a chronic condition. 
Via Investor's Business Daily
Liquidia Analysts Raise Their Forecasts Following Q2 Results
 
Via Benzinga
12 Analysts Have This To Say About Liquidia
 
Via Benzinga
Earnings Preview For Liquidia
 
Via Benzinga
These Analysts Boost Their Forecasts On Liquidia
 
Via Benzinga
Breaking Down Liquidia: 12 Analysts Share Their Views
 
Via Benzinga
Earnings Scheduled For May 8, 2025
 
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga
Why Is Liquidia Stock Trading Higher On Tuesday?
Liquidia Q2 sales hit $8.84 million after Yutrepia launch; PH-ILD study shows stable tolerability and improved walking distance at week 16. 
Via Benzinga
Liquidia Shoots Higher, But At-Risk Launch Could Come Back To Haunt It
The company is working through a patent battle that could seriously hamper sales of its new drug. 
Via Investor's Business Daily
Topics Intellectual Property
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
 
Via Benzinga
Insmed Is Trading At A 25-Year High. Will Its 'Skeleton Key' Work?
Shares are trading at a 25-year high ahead of what could be the first approval for a drug with a massive pipeline in front of it. 
Via Investor's Business Daily
Earnings Scheduled For August 12, 2025
 
Via Benzinga
Dow Gains 50 Points; US Small Business Optimism Index Rises In May
 
Via Benzinga
Topics Stocks
10 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
 
Via Benzinga
Which stocks are moving on Tuesday?
Intrigued by the market activity in the middle of the day on Tuesday? Uncover the key winners and losers of today's session in our insightful analysis. 
Via Chartmill
Which stocks are gapping on Tuesday?
Investors and traders are closely monitoring the gap up and gap down stocks in today's session on Tuesday. Let's explore the market movements and identify the stocks with significant gaps. 
Via Chartmill
Insmed Catapults Into Breakout Territory On A 'Home Run' For Its Rival To United, Liquidia
Shares look likely to break out at the open after the biotech company unveiled promising results for a pulmonary arterial hypertension treatment. 
Via Investor's Business Daily
These stocks that are showing activity before the opening bell on Tuesday.
Let's have a look at what is happening on the US markets before the opening bell on Tuesday. Below you can find the top gainers and losers in today's pre-market session. 
Via Chartmill
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
 
Via Benzinga
Vera Therapeutics, Applied Digital, Kymera Therapeutics And Other Big Stocks Moving Higher On Monday
 
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
 
Via Benzinga
Friday's after hours session: top gainers and losers
After the closing bell on Friday, let's take a glimpse of the US markets and explore the top gainers and losers in today's after-hours session. 
Via Chartmill
Liquidia Scores FDA Nod For Lung Disease Drug Yutrepia, Faces Legal Challenge
Liquidia gains FDA approval for Yutrepia to treat PAH and PH-ILD, with funding in place despite ongoing patent litigation with United Therapeutics 
Via Benzinga
Topics Intellectual Property
Liquidia Retail Buzz Surges After BofA Raises Price Target to $25 On Yutrepia FDA Nod
The company’s proprietary dry-powder formulation, supported by Phase 3 data, is viewed as a promising alternative to United Therapeutics’ Tyvaso, though legal challenges remain pending. 
Via Stocktwits
Topics Intellectual Property
12 Health Care Stocks Moving In Monday's Intraday Session
 
Via Benzinga
Where Liquidia Stands With Analysts
 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.